As such, the comparable HRs for disease recurrence between TPS < 1% and TPS ≥ 1% suggest that nivolumab adjuvant therapy exhibited consistent effectiveness regardless of tumor-cell PD-L1 expression in the CheckMate 577 trial. Here, CD274 is linked to neoplasm.